Background
The c-Myc oncoprotein is activated in the majority of colorectal cancers (CRCs), whereas the TGF-β pathway is frequently affected by loss-of-function mutations, for example in SMAD2/3/4 genes. The canonical model places Myc downstream of inhibitory TGF-β signaling. However, we previously demonstrated that Myc also inhibits TGF-β signaling through the miR-17~92 microRNA cluster, raising the question about functional relationships between these two pathways.
Methods
We engineered a series of genetically complex murine and human CRC cell lines in which Myc and TGF-β activities could be manipulated simultaneously. This was achieved through retroviral expression of the Myc-estrogen receptor fusion protein and through Smad4 short hairpin RNA knockdown. Cell lines thus modified were injected subcutaneously in immunocompromised mice, and the resultant tumors (n = 5-10 per treatment group) were analyzed for overall growth and neovascularization. Additionally, the distribution of MYC and TGF-β pathway mutations was analyzed in previously profiled human CRC samples.
Results
In kras-mutated/trp53-deleted murine colonocytes, either Myc activation or TGF-β inactivation increased tumor sizes and microvascular densities approximately 1.5-to 2.5-fold, chiefly through downregulation of thrombospondin-1 and related type I repeat-containing proteins. Combining Myc activation with TGF-β inactivation did not further accelerate tumorigenesis. This redundancy and the negative effect of TGF-β signaling on angiogenesis were also demonstrated using xenografts of human CRC cell lines. Furthermore, the analysis of the Cancer Genome Atlas data revealed that in CRC without microsatellite instability, overexpression of Myc and inactivation of Smads (including acquired mutations in SMAD2) are mutually exclusive, with odds ratio less than 0.1.
Conclusions
In human CRC, gain-of-function alterations in Myc and loss-of-function alterations in TGF-β exhibit a masking epistatic interaction and are functionally redundant. The c-Myc oncoprotein is central to the pathogenesis of colorectal cancers (CRCs), in which it is frequently overexpressed because of activating mutations in the WNT pathway or, less commonly, through MYC gene amplification (1) . To determine how MYC functions in genetically complex CRC, we had previously established a novel syngeneic mouse model based on sequential transformation of p53-null primary colonocytes with mutant Ki-Ras and Myc. In this model, Myc was dispensable for proliferation but conferred upon neoplastic cells a hypervascular phenotype (2) . This occurred through downregulation of thrombospondin-1 (Tsp-1) and related antiangiogenic factors of the type I repeat (TSR) superfamily, such as CTGF (3) . Of note, their downregulation was not simply promoter based but required upregulation of the miR-17~92 microRNA cluster by Myc (2) . Conversely, many antiangiogenic TSR proteins are induced by TGF-β (4) (5) (6) . This implied that TGF-β signaling could be antiangiogenic in the context of CRC and that Myc needs to counteract these antiangiogenic effects during tumorigenesis.
To test this bipartite hypothesis, we transduced a variety of CRC cell lines with retro-and lentiviruses encoding Myc, its tamoxifeninducible variant (MycER TAM ), and short hairpin RNAs (shRNAs) targeting Smad4, the essential component of TGF-β signaling. We discovered that either Myc activation or TGF-β inactivation, but not both, is needed to promote angiogenesis and tumor growth. This redundancy was further corroborated by Cancer Genome Atlas data showing a surprising mutual exclusivity of gain-of-function mutations in MYC and loss-of-function mutations in various SMAD genes.
protein. Propagation and treatment of these and other cell lines are described in the Supplementary Methods (available online).
Virus Infection, shRNA Knockdown, and Rescue RasMycER cells were infected with the PLKO.1 lentiviruses expressing variously effective shRNAs against mouse Smad4. SH-cont (with a nontargeting hairpin) and SH-Smad4 cell lines were generated. SW837 cells were similarly infected with the PLKO.1 lentiviruses expressing shRNA against human Myc, human Smad4, or firefly luciferase. See the Supplementary Methods (available online) for further details.
Tumor Xenograft Studies
To generate murine carcinomas, 1-2 × 10 6 RasMycER colonocytes, HCT116 cells, or SW837 cells resuspended in 100 µL of phosphate-buffered saline were injected subcutaneously into the flanks of NSG (NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ) mice aged 8 to 12 weeks. Mice of either sex from the in-house breeding facility were used. When indicated, 1 mg of tamoxifen (Sigma, St. Louis, MO) resuspended in corn oil was administered by daily intraperitoneal injection. At least five mice were used per group in all animal studies (see the Supplementary Methods, available online). All animal protocols were approved by the Children's Hospital of Philadelphia Animal Care and Use Committee (protocol 2012-12-902).
Immunohistochemistry and Vessel Quantitation
Anti-CD34 (Abcam, Cambridge, MA; Ab8158 and Ab81289) staining was performed on paraffin-embedded tumor sections using standard procedures. Microvessel density analysis was performed either using Aperio Positive Pixel Count Algorithm (version 9.1; Leica, Buffalo Grove, IL) or manually by two separate investigators on digitally scanned slide images (see the Supplementary Methods, available online).
Quantitative Real-Time Polymerase Chain Reaction Analysis RNA extraction, cDNA synthesis, and Sybr green quantitative real-time polymerase chain reaction (qPCR) for CTGF or Taqman qPCR for microRNAs was performed as described in the Supplementary Materials (available online) and previously (5) .
Immunoblotting
Cultured cells were lysed in plates, and frozen tumors were crushed to a fine powder then extracted using radioimmunoprecipitation assay (RIPA) buffer. Western blotting was carried out as described in the Supplementary Methods (available online) and previously (2, 4) .
CRC Patient Studies
Primary data for this analysis have been published previously (1) and are stored in Cancer Genomics Hub (https://cghub.ucsc. edu/, last accessed on 02/26/2014). Mutations, putative copynumber alterations from GISTIC, and/or mRNA expression data (RNASEQ; z score = 2) of complete nonhypermutated patient samples (n = 165) were analyzed using cBioPortal for Cancer Genomics platform (http://www.cbioportal.org/public-portal/, last accessed on 02/26/2014) (7, 8) . OncoPrints, copy number variation-RNA sequencing (CNV-RNASEQ) correlation plots, and mutual exclusivity odds ratio (ORs) were reported out. Access to Cancer Genome Atlas datasets was approved by the Responsible Data Access Committee of National Center for Biotechnology Information (NCBI) database of Genotypes and Phenotypes (dbGAP) (request 15694-5).
Statistics
Most statistical analyses were performed using one-way analysis of variance (ANOVA) or Tukey's test. Two-way ANOVA was also performed to determine the interactions between MYC expression and TGF-β signaling. Type III two-way ANOVA was used to analyze experiments with different sample sizes. All statistical tests were two-sided when applicable, and a P value of less than .05 was considered statistically significant. When tumors became palpable, animals were randomized, with one group receiving vehicle alone, whereas two others received tamoxifen. After 9 days, tamoxifen was discontinued in one of these latter groups. At 3 weeks, all animals were euthanized, and the tumors were weighed and processed for histology. Activation of Myc resulted in a statistically significant enhancement of tumor growth (1.7-fold difference on day 25; P < .001) ( Figure 1C , blue vs purple lines). Moreover, Myc hyperactivity was continuously required because tumor growth immediately slowed in mice that stopped receiving tamoxifen (P = .27) ( Figure 1C Figure 1F ). In agreement with our previous findings (2,4), miR-18 and miR-20, representative members of the Tsp-1-targeting miR17~92 microRNA cluster, were markedly elevated in tumors with MycER activation (P = .01 for miR-18; P = .05 for miR-20) (Figure 1G ), where they could contribute to the observed reduction in Tsp-1.
To test whether Tsp-1 is causally involved in Myc-dependent tumor growth, we replenished the tumor microenvironment with Tsp-1-based peptides. Mice with palpable subcutaneous RasMycER tumors were treated by daily intraperitoneal injections of the Tsp-1 peptide mimetic 3TSR (9) identical to the 3TSR results (1.7-fold difference in Tam-treated mice) ( Figure 1I ).
Myc and TGF-β Effects in Genetically Complex Murine CRC Cells
Although Tsp-1 was easily detected by immunoblotting in RasMycER tumor lysates, it was not detectable in cultured cells unless they were treated with TGF-β1. However, upon activation of Myc with tamoxifen, TGF-β1 induction of Tsp-1 was almost completely blocked ( Figure 2A ). We then asked what effect blocking TGF-β signaling would have in the absence or presence of activated Myc.
To this end, we infected RasMycER colonocytes with several lentiviruses expressing shRNAs against mouse Smad4 and obtained stable cell populations through puromycin selection. Among the constructs, one shRNA reduced Smad4 levels very effectively, whereas another, chosen as a negative control, did not ( Figure 2B ). Treatment of these two cell lines in vitro with TGF-β1 showed a profound dampening of TGF-β1 induction of CTGF by the Smad4-targeting but not the control shRNA. Furthermore, activation of MycER inhibited CTGF induction in shRNA control cells but had little effect in cells with Smad4 shRNA, where induction was already abolished ( Figure 2C ). To rule out nonspecific effects of the anti-Smad4 hairpin, we rescued Smad4 expression using the human ortholog, which does not contain the short hairpin target sequence. Transduction with this rescue construct increased basal CTGF levels and also restored robust induction of CTGF by TGF-β ( Figure 2D) . Again, the induction of CTGF was strongly blunted in the presence of Myc ( Figure 2D , two rightmost lanes)
Next, RasMycER cells expressing control and α-Smad4 shRNA were used to generate tumors in either tamoxifen-or vehicle-treated mice. Activation of MycER in tumors expressing the control shRNA resulted in markedly reduced levels of all TSR family proteins assayed, including Tsp-1, CTGF, and clusterin, whereas Smad4 levels were maintained ( Figure 2E, left panel) . In contrast, in Smad4-deficient tumors, the protein levels of Tsp-1, CTGF, and clusterin were greatly reduced even in the absence of tamoxifen because of inactive TGF-β signaling ( Figure 2E, right panel) . Notably, low TSR protein levels tracked with large tumor sizes (SH-cont vehicle vs tamoxifen: 2.3-fold difference, P = .003; SH-Smad4 vehicle vs tamoxifen: 1.2-fold difference, P = .65) ( Figure 2F ; see replicate experiment in Supplementary Figure 1C , available online). To determine whether robust vascularity also tracked with low TSR protein levels, we stained tumor sections with the anti-CD34 antibody. Regardless of whether the reduced TSR expression was due to MycER activation or Smad4 knockdown, resultant tumors had markedly higher microvessel densities than tumors with robust TSR expression (SH-cont vehicle vs tamoxifen: 1.8-fold difference, P = .02; SH-Smad4 vehicle vs tamoxifen: 1.2-fold difference, P = .21) (Figure 2, G and H) . The concordance between tumor sizes and neovascularization suggested that MYC-driven angiogenesis is limiting to tumor growth.
Activation of MYC and Loss-of-Function Mutations in the TGF-β Pathway in Human CRC Cell Lines
We thus asked whether Myc regulates TGF-β1 induction of Tsp-1 in human CRC cells. Because most commonly used human CRC cell lines are impaired in that pathway because of mutations in either the TGF-β type II receptor and Smad2/3/4 or polymorphisms in type I receptor (11, 12) , we first tested several human colonic epithelial cell lines that were reported either to have the intact TGF-β signaling pathway (SW837 CRC cells) (13) or to be nontumorigenic (NCM356 and NCM460 cells) (14) . Stimulation of each of these three cell lines for 1 hour with 5 ng/mL of TGF-β1 resulted in phosphorylation of receptor-regulated Smads (ie, Smad2 and Smad3) ( Figure 3A) . However, although Smad4 was robustly expressed in SW837 cells, we saw no detectable expression of Smad4 in NCM356 and NCM460 cells. Moreover, 48-hour treatment with TGF-β1 induced expression of both Tsp-1 and CTGF only in SW837 cells ( Figure 3A) .
We used the SW837 model to determine whether high levels of endogenous Myc protein [presumably due to the APC mutation (15)] were limiting TGF-β1-induced expression of TSR proteins. Using the chemical inhibitor of BET bromodomains JQ1 (16,17), we were able to inhibit c-Myc expression in SW837 cells to the same degree as achieved by infection with a lentivirus expressing an anti-MYC shRNA ( Figure 3B ). When SW837 cells were treated with a suboptimal (0.5 ng/mL) amount of TGF-β1 after pretreatment with JQ1, CTGF was induced more robustly, both at the RNA and the protein levels (P < .001) ( Figure 3C ). The interaction between TGF-β1 and JQ1 treatments was statistically significant per two-way ANOVA (P < .001). To determine the functional significance of reduced TGF-β signaling for tumor growth, we knocked down Smad4 expression in SW837 cells using two independent hairpins ( Figure 3D ). Both shRNAs strongly inhibited induction of CTGF by TGF-β ( Figure 3E ). When implanted in mice, cells with Smad4 knockdown formed larger tumors (shRNA #4 vs. control: 8.2-fold difference, P = .006; shRNA #6 vs. control: 2.5-fold difference, P = .006) (Figure 3 , F and G). This was accompanied by a markedly increased vascularization (shRNA #4 vs. control: 3.0-fold difference, P < .001; shRNA #6 vs. control: 3.1-fold difference, P < .001) (Figure 3, H, I , and J).
To directly compare the effects of Myc overexpression and TGF-β inactivation, we chose to use a cell line without the APC mutation and, consequently, with relatively modest basal levels of Myc [despite the activating Ser-45 deletion in CTNNB1, the positive regulator of MYC (15)]. HCT116 cells are known to have a homozygous mutation in the mismatch repair gene hMLH1 on human chromosome 3 and exhibit microsatellite instability leading to inactivation of the TGF-βRII gene (located on the same chromosome) ( Figure 4A ). However, there is an engineered derivative (HCT116:3-6) in which both hMLH1 and TGF-βRII expression have been restored through the transfer of a single chromosome 3 from normal fibroblasts ( Figure 4B) (18, 19) . We introduced a Myc-expression vector into both HCT116 and HCT116:3-6 cells by means of retroviral transduction ( Figure 4C ). As anticipated, treatment with TGF-β caused Smad2 and Smad3 phosphorylation in the latter but not the former ( Figure 4D ). Moreover, Myc overexpression reduced levels of pSmad3 and, to a lesser extent, pSmad2. As we described previously (20) , in cultured HCT116 cells, the basal levels of Tsp-1 are very low, making CTGF a more reliable readout. Notably, in HCT116:3-6 cells, Myc strongly blocked induction of CTGF, which is an important functional readout for TGF-β signaling ( Figure 4D) .
Additionally, MYC presence did not affect cell accumulation of either untreated HCT116 or HCT116:3-6 cells in vitro ( Figure 4E ). However, activating the TGF-β signaling pathway in vector-only HCT116:3-6 reduced cell accumulation, and this reduction was completely rescued by Myc overexpression (P < .001) ( Figure 4F , compare green and purple plots). Conversely, omission of chromosome 3 rendered Myc overexpression completely redundant (P = .63) ( Figure 4F , compare blue and red plots). To see whether these opposing effects of MYC and TGF-β on cell accumulation would also manifest themselves in vivo, HCT116 and HCT116:3-6 cells, with or without MYC, were used to produce subcutaneous xenografts, which are exposed to TGF-β stimulation (see Figure 2E ). Once again, we observed that Myc overexpression enhanced tumor growth only in the presence of functional TGF-β signaling (1.7-fold difference, P = .02) (HCT116:3-6 xenografts in Figure 4G , compare green and purple symbols) and was redundant in the context of TGF-β-deficient HCT116 cells (1.2-fold 
Overexpression of MYC and inactivation of SMADs in primary human CRCs.
To determine how relevant our syngeneic and xenograft systems were to human cancers, we analyzed the co-occurrence of APC, MYC, RAS, and TP53 mutations in primary human samples profiled in the recent Cancer Genome Atlas study (1) . To avoid analyzing samples with hundreds of passenger mutations, we limited our analysis to 165 comprehensively characterized tumors without microsatellite instability. Such tumors do not usually accumulate mutations in TGFBR2 (21) but inactivate one of the Smads, most frequently Smad4 and Smad2 (1) . Additionally, to exclude A) OncoPrint of MYC, KRAS, TP53, and APC mutations, putative copynumber alterations from GISTIC and mRNA expression data (RNASEQ; z score = 2) of complete nonhypermutated CRC patient samples, which were analyzed using the cBioPortal for Cancer Genomics platform. One hundred fifty-seven (95%) cases had mutations in either or all of the genes analyzed. Odds ratios (ORs), indicating the tendency for MYC amplification/overexpression to co-occur with KRAS, TP53, and APC mutations, putative copy-number alterations, and changes in mRNA expression are shown (right). B) MYC, SMAD2, SMAD3, and SMAD4 mRNA expression data (RNASEQ; z score = 2) of complete nonhypermutated CRC patient samples in A were analyzed against their putative copy-number alterations (CNA, from GISTIC). Missense and nonsense mutations are represented by red circles and black diamonds (red outline), respectively. C) OncoPrint of MYC, SMAD2, SMAD3, and SMAD4 mRNA expression data (RNASEQ; z score = 2) of complete nonhypermutated CRC patient samples in A. Fifty-three (32%) cases had changes in the mRNA expression for the genes analyzed. The odds ratios for MYC overexpression to be mutually exclusive from alterations in SMAD2/3/4 mRNA expression are indicated (right). D) OncoPrint and odds ratio of MYC, SMAD2, SMAD3, and SMAD4 mutations and mRNA expression data (RNASEQ; z score = 2) of complete nonhypermutated CRC patient samples in A. Seventy-three (44%) cases had alterations in the genes of interest. In this analysis, MYC overexpression and Smad2 mutation/ mRNA downregulation were mutually exclusive. Statistical significance per Fisher's exact test: P = .02.
cases with MYC amplification but no overexpression, we used RNASEQ values as a surrogate marker for MYC copy number variations. As predicted (15) , there was a strong association (OR > 10) between MYC overexpression and APC mutations. We also observed an association (OR = 2-10) between MYC overexpression and inactivating mutations in TP53 ( Figure 5A ). Overall, 20% (n = 33 cases) of tumors without microsatellite instability harbor oncogenic mutations in all three CRC genes-APC, KRAS and TP53-further validating our murine RasMycER colonocyte and SW837 models.
We then asked whether overexpression of MYC and inactivation of SMADs are mutually exclusive, as predicted by our model. Again, to exclude cases with copy number variations but no deregulation at the mRNA levels ( Figure 5B ), RNASEQ values were used to assess expression levels. For both SMAD2 and SMAD3, we observed strong tendency toward mutual exclusivity with MYC activation (OR < 0.1). A weaker tendency was observed for SMAD4 (OR = 0.1-0.5) ( Figure 5C ). We then included inactivating point mutations in this analysis. We found that, of the three SMADs, only SMAD2 mutations exhibited strong tendency toward mutual exclusivity (OR < 0.1) ( Figure 5D ). This was in agreement with the observation that MYC exerts stronger effect on phosphorylation of Smad3 than Smad2 (Figure 4D ), perhaps necessitating genetic inactivation in the latter case. Interestingly, when the same analysis was repeated on microsatellite-unstable tumors, we saw no evidence of Myc deregulation, although other CRC cancer genes and components of the TGF-β pathways were mutated as expected (Supplementary Figure 2 , B and C, available online).
Discussion
Although CRC patient outcomes have been improving, 5-year survival rates remain at approximately 10% for stage IV CRC with distant metastasis, necessitating major therapeutic advances (22) . Much hope is hinging on next-generation sequencing and other systems biology approaches to CRC analysis (23, 24) . Just 18 months ago, the Cancer Genome Atlas reported genome-scale analysis of 276 samples, including exome sequence, DNA copy number, promoter methylation, and messenger RNA and micro-RNA expression (1) . This in-depth analysis revealed several new therapeutic targets and also underscored the importance of WNT and TGF-β pathways, which ultimately converge on MYC.
Admittedly, TGF-β plays complex and often contradictory roles in disease in general and cancer in particular (25, 26) . Its tumor suppressive role is most commonly attributed to inhibition of cell proliferation (27) . However, in addition to this cell-intrinsic effect, TGF-β clearly plays a role in epithelial-mesenchymal transition, invasion, metastasis, and other cell-extrinsic phenotypes (28) (29) (30) . This complexity is due, at least in part, to TGF-β-tumor microenvironment interactions, examples of which are beginning to emerge (31) . Interestingly, depending on context, TGF-β has been ascribed either pro-or antiangiogenic activities [reviewed in (32) ]. The majority of recent articles appear to emphasize proangiogenic effects of TGF-β, to the point of suggesting that ongoing clinical trials of TGF-β inhibitors [eg, fresolimumab (33)] could reveal their antiangiogenic effects (34) . Nevertheless, our data argue, at least in the context of CRC, that TGF-β inhibits neovascularization, that antiangiogenesis strongly contributes to the overall tumor-suppressive effects of TGF-β, that MYC must counteract these effects to promote neoplastic growth, and that in the absence of TGF-β signaling the importance of MYC would be greatly diminished.
One limitation of our study is that angiogenesis was tested in subcutaneous xenograft models, in which blood vessels are different in several respects (including poor pericyte coverage) from those found in autochthonous tumors (35) . Furthermore, because we wanted to measure tumor growth longitudinally, we implanted CRC cells subcutaneously, not in an orthotopic environment of the cecal wall (2) . Finally, although the microvessel density is a commonly used descriptor of tumor vasculature, we have yet to measure the effects of TGF-β on tumor tissue perfusion and hypoxia, which play important roles in tumorigenesis.
Nevertheless, we were able to validate our key finding in spontaneous human tumors by demonstrating that CRCs with very high MYC levels are devoid of common SMAD mutations. This suggested a surprising redundancy between gain-of-function mutations in the MYC pathway and loss-of-function mutations in the TGF-β pathway. The paramount importance of this axis for Myc-driven colon cancer was surprising, given the pleiotropic effects of Myc on neoplastic growth. These findings also have implications for cancer therapeutics. Small molecule inhibitors of bromodomain proteins (eg, I-BET151 and JQ1) have shown efficacy against assorted leukemias and Burkitt's lymphoma, in large part through profound inhibition of MYC transcription (17, 36) . These and related compounds are currently being tested in CRC patients (eg, GSK525762 in phase I clinical trial: http://www.cancer.gov/clinicaltrials/search/res ults?protocolsearchid=10450167, last accessed February 26, 2014). However, it is currently unknown which CRC subtypes will be most susceptible to this therapy.
Of clinical relevance is the fact that most CRCs with microsatellite instability and close to 15% of CRCs with chromosomal instability lack functional TGF-β signaling (1). The evidence for masking epistasis, uncovered in our study, would argue that such patients may not benefit from MYC-targeting drugs as much as patients with TGFBR2/SMAD-sufficient neoplasms and that other therapeutic options should be pursued instead. However, TGF-β deficiency might serve as a biomarker of sensitivity to TSR mimetics (37) , which can be construed as an effective TGF-β target replacement therapy. 
